Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Genomic Advances in Sepsis (GAinS) study has been recruiting intensive care patients with sepsis for further study for over a decade. The project was initiated by the UK Critical Care Genomics group in 2005 to characterise genetic variants that affect susceptibility to and outcomes from sepsis. Sepsis is a life-threatening complication of infection caused by a dysregulated host immune response leading to organ failure. It affects an estimated 30 million people worldwide each year, and is recognised as a global health priority by the World Health Organisation. Over 2000 patients with sepsis have been enrolled to the GAinS study with a recent exciting collaborative opportunity with Genomics England, recruiting patients to the 100,000 genomes project. Current work uses a multi-omics approach to explore the sepsis response and the GAinS researchers have recently launched a new website for both patients/relatives and researchers to describe their ongoing work.